• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

    6/1/25 8:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email

    – Long-Term Analysis Shows Similar Safety and Effectiveness Outcomes in Outpatient vs. Inpatient Setting with Positive Impact for Healthcare Systems –

    Kite, a Gilead Company (NASDAQ:GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta® (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) assigned to treatment in an outpatient setting (no planned hospital stay) versus those assigned to an inpatient setting in a hospital. The analysis, based on data collected from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, observed that safety and effectiveness outcomes for people treated as outpatients were comparable to those patients who received treatment in a hospital. The results were shared in a presentation (Abstract #7023) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

    "The encouraging results from this study corroborate reports from treatment centers and prior studies in the real world that illustrate the potential feasibility of administering axi-cel in the outpatient setting for people with relapsed or refractory large B-cell lymphoma," said Dr. Fateeha Furqan, lead investigator, The University of Texas MD Anderson Cancer Center. "Outpatient administration of axi-cel has cost-effective advantages over inpatient treatment, including less burden on hospitals. These clinical results reflect the fact that the knowledge and experience needed to safely administer the therapy has only grown since axi-cel was first approved in 2017."

    Data were collected from the CIBMTR observational database (between July 2021 to Nov 2023). The final analysis assessed data on patients with R/R LBCL from 75 treatment centers, comparing 119 individuals who were assigned to receive Yescarta in the outpatient setting to 119 patients assigned to receive Yescarta in the inpatient setting. With a median follow-up of 12 months, no general differences were found between the 2 groups in the rates of cytokine release syndrome, neurologic events or immune effector cell-associated neurotoxicity syndrome grade ≥ 3.

    Almost one-fourth of 119 patients who were assigned to receive Yescarta in the outpatient setting did not require hospital admission within 30 days, and half of 119 patients did not require hospital admission within 3 days based on propensity score-matched dataset. These real-world data are not currently in the U.S. Prescribing Information.

    "We are seeing a growing body of evidence that suggests outpatient administration of Yescarta could be reliable and safe in suitable settings, with benefits for the patient, their family and healthcare system," said Dominique Tonelli, M.D., Vice President and Global Head of Medical Affairs, Kite. "We are confident that these promising results will help inform providers to expand the number of patients who can achieve the curative potential of a one-time treatment with Yescarta."

    Patients assigned to the outpatient and inpatient treatment groups were matched by age, sex, comorbidities, lactate dehydrogenase (LDH), bulky disease, prior lines of therapy, chemosensitivity and infusion year. Patients assigned to the outpatient group had a median age of 63 years (25% ≥ 70), 66% were male and 67% had ≥ 1 comorbidity. Half had elevated LDH and 73% had 1 prior line of therapy. Bulky disease was reported in 3% and 60% had chemo-resistant disease.

    About LBCL

    Globally, LBCL is the most common type of non-Hodgkin lymphoma. In the United States, more than 18,000 people are diagnosed with LBCL each year. About 30-40% of patients with LBCL will need second-line treatment, as their cancer will either relapse (return) or become refractory (not respond) to initial treatment.

    About Yescarta

    Please see full Prescribing Information, including BOXED WARNING below and Medication Guide.

    YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

    • Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
    • Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

    Limitations of Use: YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma.

    • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

    U.S. IMPORTANT SAFETY INFORMATION

    BOXED WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES and SECONDARY HEMATOLOGICAL MALIGNANCIES

    • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving YESCARTA. Do not administer YESCARTA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
    • Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving YESCARTA, including concurrently with CRS or after CRS resolution. Monitor for neurologic toxicities after treatment with YESCARTA. Provide supportive care and/or corticosteroids, as needed.
    • T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including YESCARTA.
    • YESCARTA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the YESCARTA and TECARTUS REMS Program.

    CYTOKINE RELEASE SYNDROME (CRS)

    CRS, including fatal or life-threatening reactions, occurred following treatment with YESCARTA. CRS occurred in 90% (379/422) of patients with non-Hodgkin lymphoma (NHL) receiving YESCARTA, including ≥ Grade 3 (Lee grading system1) CRS in 9%. CRS occurred in 93% (256/276) of patients with large B-cell lymphoma (LBCL), including ≥ Grade 3 CRS in 9%. Among patients with LBCL who died after receiving YESCARTA, four had ongoing CRS events at the time of death. For patients with LBCL in ZUMA-1, the median time to onset of CRS was 2 days following infusion (range: 1 to 12 days) and the median duration of CRS was 7 days (range: 2 to 58 days). For patients with LBCL in ZUMA-7, the median time to onset of CRS was 3 days following infusion (range: 1 to 10 days) and the median duration was 7 days (range: 2 to 43 days).

    CRS occurred in 84% (123/146) of patients with indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5, including ≥ Grade 3 CRS in 8%. Among patients with iNHL who died after receiving YESCARTA, one patient had an ongoing CRS event at the time of death. The median time to onset of CRS was 4 days (range: 1 to 20 days) and the median duration was 6 days (range: 1 to 27 days) for patients with iNHL. Key manifestations of CRS (≥ 10%) in all patients combined included fever (85%), hypotension (40%), tachycardia (32%), chills (22%), hypoxia (20%), headache (15%), and fatigue (12%). Serious events that may be associated with CRS include, cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), renal insufficiency, cardiac failure, respiratory failure, cardiac arrest, capillary leak syndrome, multi-organ failure, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).

    The impact of tocilizumab and/or corticosteroids on the incidence and severity of CRS was assessed in two subsequent cohorts of LBCL patients in ZUMA-1. Among patients who received tocilizumab and/or corticosteroids for ongoing Grade 1 events. CRS occurred in 93% (38/41), including 2% (1/41) with Grade 3 CRS; no patients experienced a Grade 4 or 5 event. The median time to onset of CRS was 2 days (range: 1 to 8 days) and the median duration of CRS was 7 days (range: 2 to 16 days). Prophylactic treatment with corticosteroids was administered to a cohort of 39 patients for 3 days beginning on the day of infusion of YESCARTA. Thirty-one of the 39 patients (79%) developed CRS at which point the patients were managed with tocilizumab and/or therapeutic doses of corticosteroids with no patients developing Grade 3 or higher CRS. The median time to onset of CRS was 5 days (range: 1 to 15 days) and the median duration of CRS was 4 days (range: 1 to 10 days). Although there is no known mechanistic explanation, consider the risk and benefits of prophylactic corticosteroids in the context of pre-existing comorbidities for the individual patient and the potential for the risk of Grade 4 and prolonged neurologic toxicities.

    Ensure that 2 doses of tocilizumab are available prior to infusion of YESCARTA. Monitor patients at least daily for 7 days at the certified healthcare facility following infusion for signs and symptoms of CRS. Monitor patients for signs or symptoms of CRS for 4 weeks after infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated.

    NEUROLOGIC TOXICITIES

    Neurologic toxicities (including immune effector cell-associated neurotoxicity syndrome) that were fatal or life- threatening occurred. Neurologic toxicities occurred in 78% (330/422) of all patients with NHL receiving YESCARTA, including ≥ Grade 3 in 25%. Neurologic toxicities occurred in 87% (94/108) of patients with LBCL in ZUMA-1, including ≥ Grade 3 in 31% and in 74% (124/168) of patients in ZUMA-7 including ≥ Grade 3 in 25%. The median time to onset was 4 days (range: 1-43 days) and the median duration was 17 days for patients with LBCL in ZUMA-1. The median time to onset for neurologic toxicity was 5 days (range:1- 133 days) and median duration was 15 days in patients with LBCL in ZUMA-7. Neurologic toxicities occurred in 77% (112/146) of patients with iNHL, including ≥ Grade 3 in 21%. The median time to onset was 6 days (range: 1-79 days) and the median duration was 16 days. Ninety-eight percent of all neurologic toxicities in patients with LBCL and 99% of all neurologic toxicities in patients with iNHL occurred within the first 8 weeks of YESCARTA infusion. Neurologic toxicities occurred within the first 7 days of infusion for 87% of affected patients with LBCL and 74% of affected patients with iNHL.

    The most common neurologic toxicities (≥ 10%) in all patients combined included encephalopathy (50%), headache (43%), tremor (29%), dizziness (21%), aphasia (17%), delirium (15%), and insomnia (10%). Prolonged encephalopathy lasting up to 173 days was noted. Serious events, including aphasia, leukoencephalopathy, dysarthria, lethargy, and seizures occurred. Fatal and serious cases of cerebral edema and encephalopathy, including late-onset encephalopathy, have occurred.

    The impact of tocilizumab and/or corticosteroids on the incidence and severity of neurologic toxicities was assessed in 2 subsequent cohorts of LBCL patients in ZUMA-1. Among patients who received corticosteroids at the onset of Grade 1 toxicities, neurologic toxicities occurred in 78% (32/41) and 20% (8/41) had Grade 3 neurologic toxicities; no patients experienced a Grade 4 or 5 event. The median time to onset of neurologic toxicities was 6 days (range: 1-93 days) with a median duration of 8 days (range: 1-144 days). Prophylactic treatment with corticosteroids was administered to a cohort of 39 patients for 3 days beginning on the day of infusion of YESCARTA. Of those patients, 85% (33/39) developed neurologic toxicities, 8% (3/39) developed Grade 3, and 5% (2/39) developed Grade 4 neurologic toxicities. The median time to onset of neurologic toxicities was 6 days (range: 1-274 days) with a median duration of 12 days (range: 1-107 days). Prophylactic corticosteroids for management of CRS and neurologic toxicities may result in higher grade of neurologic toxicities or prolongation of neurologic toxicities, delay the onset and decrease the duration of CRS.

    Monitor patients for signs and symptoms of neurologic toxicities at least daily for 7 days at the certified healthcare facility, and for 4 weeks thereafter, and treat promptly.

    REMS

    Because of the risk of CRS and neurologic toxicities, YESCARTA is available only through a restricted program called the YESCARTA and TECARTUS REMS Program which requires that: Healthcare facilities that dispense and administer YESCARTA must be enrolled and comply with the REMS requirements and must have on-site, immediate access to a minimum of 2 doses of tocilizumab for each patient for infusion within 2 hours after YESCARTA infusion, if needed for treatment of CRS. Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense, or administer YESCARTA are trained about the management of CRS and neurologic toxicities. Further information is available at www.YescartaTecartusREMS.com or 1-844-454-KITE (5483).

    HYPERSENSITIVITY REACTIONS

    Allergic reactions, including serious hypersensitivity reactions or anaphylaxis, may occur with the infusion of YESCARTA.

    SERIOUS INFECTIONS

    Severe or life-threatening infections occurred. Infections (all grades) occurred in 45% of patients with NHL. Grade 3 or higher infections occurred in 17% of patients, including ≥ Grade 3 or higher infections with an unspecified pathogen in 12%, bacterial infections in 5%, viral infections in 3%, and fungal infections in 1%. YESCARTA should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines. Febrile neutropenia was observed in 36% of all patients with NHL and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.

    In immunosuppressed patients, including those who have received YESCARTA, life-threatening and fatal opportunistic infections including disseminated fungal infections (e.g., candida sepsis and aspergillus infections) and viral reactivation (e.g., human herpes virus-6 [HHV-6] encephalitis and JC virus progressive multifocal leukoencephalopathy [PML]) have been reported. The possibility of HHV-6 encephalitis and PML should be considered in immunosuppressed patients with neurologic events and appropriate diagnostic evaluations should be performed. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells, including YESCARTA. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.

    PROLONGED CYTOPENIAS

    Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and YESCARTA infusion. ≥ Grade 3 cytopenias not resolved by Day 30 following YESCARTA infusion occurred in 39% of all patients with NHL and included neutropenia (33%), thrombocytopenia (13%), and anemia (8%). Monitor blood counts after infusion.

    HYPOGAMMAGLOBULINEMIA

    B-cell aplasia and hypogammaglobulinemia can occur. Hypogammaglobulinemia was reported as an adverse reaction in 14% of all patients with NHL. Monitor immunoglobulin levels after treatment and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement. The safety of immunization with live viral vaccines during or following YESCARTA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during YESCARTA treatment, and until immune recovery following treatment.

    SECONDARY MALIGNANCIES

    Patients treated with YESCARTA may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including YESCARTA. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes.

    Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.

    EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

    Due to the potential for neurologic events, including altered mental status or seizures, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following YESCARTA infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.

    ADVERSE REACTIONS

    The most common non-laboratory adverse reactions (incidence ≥ 20%) in patients with LBCL in ZUMA-7 included fever, CRS, fatigue, hypotension, encephalopathy, tachycardia, diarrhea, headache, musculoskeletal pain, nausea, febrile neutropenia, chills, cough, infection with unspecified pathogen, dizziness, tremor, decreased appetite, edema, hypoxia, abdominal pain, aphasia, constipation, and vomiting.

    The most common adverse reactions (incidence ≥ 20%) in patients with LBCL in ZUMA-1 included CRS, fever, hypotension, encephalopathy, tachycardia, fatigue, headache, decreased appetite, chills, diarrhea, febrile neutropenia, infections with pathogen unspecified, nausea, hypoxia, tremor, cough, vomiting, dizziness, constipation, and cardiac arrhythmias.

    The most common non-laboratory adverse reactions (incidence ≥ 20%) in patients with iNHL in ZUMA-5 included fever, CRS, hypotension, encephalopathy, fatigue, headache, infections with pathogen unspecified, tachycardia, febrile neutropenia, musculoskeletal pain, nausea, tremor, chills, diarrhea, constipation, decreased appetite, cough, vomiting, hypoxia, arrhythmia, and dizziness.

    About Kite

    Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing. For more information on Kite, please visit www.kitepharma.com.

    About Gilead Sciences

    Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif. Gilead acquired Kite in 2017.

    Forward-Looking Statements

    This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of Gilead and Kite to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical studies, including those involving Yescarta; uncertainties relating to regulatory applications and related filing and approval timelines, including pending or potential applications for indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.

    Yescarta, Gilead, the Gilead logo, Kite, and the Kite logo are trademarks of Gilead Sciences, Inc., or its related companies.

    For more information on Kite, please visit the company's website at www.kitepharma.com. Follow Kite on social media on X (@KitePharma) and LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250601431400/en/

    Blair Baumwell, Media

    [email protected]

    Jacquie Ross, Investors

    [email protected]

    Get the next $GILD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GILD

    DatePrice TargetRatingAnalyst
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    3/4/2025$115.00 → $132.00Outperform
    Oppenheimer
    2/18/2025$120.00Hold → Buy
    Deutsche Bank
    2/13/2025$108.00Hold → Buy
    DZ Bank
    1/10/2025$87.00 → $113.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$109.00Buy
    BofA Securities
    11/15/2024$110.00Outperform
    Wolfe Research
    11/14/2024$125.00Buy
    Citigroup
    More analyst ratings

    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

      – Long-Term Analysis Shows Similar Safety and Effectiveness Outcomes in Outpatient vs. Inpatient Setting with Positive Impact for Healthcare Systems – Kite, a Gilead Company (NASDAQ:GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta® (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) assigned to treatment in an outpatient setting (no planned hospital stay) versus those assigned to an inpatient setting in a hospital. The analysis, based on data collected from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, observed that safety and effectiveness outcomes for people trea

      6/1/25 8:00:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

      – First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC – – Early Trend in Improvement in Overall Survival Observed – Gilead Sciences, Inc. (NASDAQ:GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care Keytruda plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 months vs 7.8 mont

      5/31/25 8:00:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

      – Second Positive Phase 3 Trial in First-line Metastatic TNBC Where Trodelvy Has Demonstrated a Clinically Meaningful Benefit Versus Standard of Care Chemotherapy – – Trodelvy Has the Potential to Be the Backbone of Treatment and the First Antibody-Drug Conjugate for All Patients Across First-line Metastatic TNBC – Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with first-line metastatic tripl

      5/23/25 8:30:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

      11/26/24 4:36:21 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

      Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

      11/15/24 4:36:27 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Financials

    Live finance-specific insights

    See more
    • Gilead Sciences Announces First Quarter 2025 Financial Results

      Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Our base business grew 4% year-over-year, primarily led by Biktarvy's continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer. With the upcoming June P

      4/24/25 4:02:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

      Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The compa

      4/10/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend

      Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.6% in the company's quarterly cash dividend, beginning in the first quarter of 2025. The increase will result in a quarterly dividend of $0.79 per share of common stock. The dividend is payable on March 28, 2025, to stockholders of record at the close of business on March 14, 2025. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi

      2/11/25 4:05:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman & CEO O'Day Daniel Patrick sold $1,104,193 worth of shares (10,000 units at $110.42), decreasing direct ownership by 2% to 620,268 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      6/2/25 8:55:50 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Mercier Johanna exercised 25,000 shares at a strike of $66.64 and sold $3,010,564 worth of shares (28,000 units at $107.52), decreasing direct ownership by 2% to 121,152 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/23/25 3:16:26 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Dickinson Andrew D sold $249,550 worth of shares (2,500 units at $99.82), decreasing direct ownership by 1% to 165,674 units (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

      5/16/25 4:34:29 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Gilead Sciences with a new price target

      Cantor Fitzgerald resumed coverage of Gilead Sciences with a rating of Overweight and set a new price target of $125.00

      4/22/25 7:32:53 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Gilead Sciences with a new price target

      Oppenheimer reiterated coverage of Gilead Sciences with a rating of Outperform and set a new price target of $132.00 from $115.00 previously

      3/4/25 8:15:52 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences upgraded by Deutsche Bank with a new price target

      Deutsche Bank upgraded Gilead Sciences from Hold to Buy and set a new price target of $120.00

      2/18/25 7:09:02 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    SEC Filings

    See more
    • SEC Form 13F-HR filed by Gilead Sciences Inc.

      13F-HR - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/13/25 4:15:37 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/8/25 5:26:08 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Gilead Sciences Inc.

      10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/7/25 4:32:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

      SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/9/24 6:21:28 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

      SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/13/23 3:32:27 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Gilead Sciences Inc.

      SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

      2/13/23 2:49:26 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

      4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

      2/13/24 5:48:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

      Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in

      12/12/24 5:30:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

      Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa

      6/15/23 4:01:00 PM ET
      $GILD
      $GLPG
      $JNJ
      $LIVN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Electromedical & Electrotherapeutic Apparatus